Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury.

However, the serum IMA level of the I/R group showed a trend to be greater than the sham group, but this was not statistically significant (0.17 ± 0.01 A.U. vs. 0.15 ± 01 A.U., p > 0.05) ( Figure 5 d); however, treatment with rhSLPI in the rhSLPI-DI group showed, in serum, a significantly lower IMA level than that of the I/R group (0.17 ± 0.01 A.U. vs. 0.15 ± 0.01 A.U., p < 0.05) ( Figure 5 d). 3.6.

also in 53,322 other papers